New survey launched to explore the acceptability of the Gonococcal Controlled Human Infection Model in UK men.
13 January 2023
Researchers at the University of Oxford have launched a new mixed methods study to explore the acceptability of the Gonococcal Controlled Human Infection Model (GC-CHIM) in UK men.
Oxford Ebola vaccine manufactured and shipped in record time by SII
19 December 2022
More than 40,000 doses of Oxford’s Ebola vaccine have been manufactured by SII (Serum Institute of India) in just 60 days and doses shipped to Uganda.
From running COVID-19 trials to researching respiratory diseases - Daniela Ferreira discusses her journey from Brazil to Oxford
7 December 2022
Daniela Ferreira, Professor of Mucosal Immunity and Infection at the Oxford Vaccine Group, Department of Paediatrics, has so much enthusiasm for her work on respiratory infections and vaccinology, you would be very hard-pressed not to want her to succeed
It’s not just Covid: the triple threat that could overwhelm the NHS this winter - Andrew Pollard
13 September 2022
A severe flu outbreak or new coronavirus variant could prove catastrophic for a health service already on its knees
Novel all-in-one vaccine developed to tackle future coronavirus threats
6 July 2022
Up to $30 million in funding has been announced by the Coalition for Epidemic Preparedness Innovations (CEPI) to bring a new nanoparticle vaccine offering protection against a range of coronaviruses to clinical trial.
Professor Sir Andrew Pollard Awarded the James Spence Medal in 2022
1 July 2022
Professor Sir Andrew Pollard, BSc MA MBBS MRCP(UK) FRCPCH PhD DIC FHEA FIDSA FMedSci, is Professor of Paediatric Infection and Immunity at the University of Oxford, Honorary Consultant Paediatrician at Oxford Children’s Hospital and Vice Master of St Cross College, Oxford.
Com-COV vaccine study to research third dose booster options for 12-to-15-year-olds
26 May 2022
Researchers running the University of Oxford-led Com-COV programme have launched a further study of COVID-19 vaccination schedules in young people aged 12 to 15 – with a focus on assessing different options for a third dose booster vaccination.
Fourth COVID-19 vaccine dose provides stronger immunity boost than third dose, shows UK study
16 May 2022
COVID-19 vaccines given as fourth doses in the UK offer excellent boosting immunity protection, according to the latest results from a nationwide NIHR-supported study.
Oral paratyphoid vaccine to begin human trials
10 May 2022
The University of Oxford in collaboration with the University of Maryland School of Medicine (UMSoM) has begun recruiting for a Phase I/II trial of a new paratyphoid vaccine in human volunteers in Oxford.
Oxford to work with Brazil to establish clinical research hub
8 November 2021
The University of Oxford and Brazilian Ministry of Health have announced a joint initiative to set up a global health and clinical research unit in Brazil led by Professor Sue Ann Clemens CBE.
Professor Sue Ann Costa Clemens awarded an Honorary CBE
24 September 2021
Congratulations to Professor Sue Ann Costa Clemens for her Honarary CBE award for her positive contribution towards public health. Here at the Oxford Vaccine Group and the Paediatrics department, we are extremely proud of what Sue and her team have achieved.
We shouldn’t be giving Covid boosters while millions wait for a first dose
20 August 2021
There’s no evidence yet that top-up shots are needed, so let’s help those around the world who urgently need the vaccine - writes Andrew Pollard in an opinion piece for The Guardian.
University of Oxford researchers among recipients of Ireland and UK joint research awards for digital humanities in €6.5m boost for interdisciplinary research partnerships
9 August 2021
Dr Samantha Vanderslott (Oxford Vaccine Group) and Dr Claas Kirchhelle (University College Dublin) have had their three-year project ‘Typhoid, Cockles, and Terrorism’ about the history of typhoid in Dublin successfully funded.
One billion doses: A moment to celebrate but not a time to be complacent
30 July 2021
Professor Sir Andrew Pollard, Director of the Oxford Vaccine Group and Professor of Paediatric Infection and Immunity, takes a moment to reflect on one billion doses of the Oxford coronavirus vaccine released worldwide.
Severe disease, not mild infection, makes a pandemic – vaccines still offer our best hope
30 July 2021
If the current high levels of protection against severe disease are sustained, the global public health emergency will be curtailed by the ongoing vaccine rollout - writes Andrew Pollard for The Independent.
Oxford vaccine reaches one billion doses released
29 July 2021
The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.
Phase I trial begins of new vaccine against the Plague
27 July 2021
Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.
Oxford Vaccine Group among winners at NHS Parliamentary awards
9 July 2021
Awards & Appointments COVID-19
Researchers behind the Oxford AstraZeneca coronavirus vaccine have been recognised for their excellence at a healthcare awards ceremony.
New book highlights life-saving role vaccines play in prevention of killer diseases
9 July 2021
'Brain Fever', a new book by internationally-renowned medical scientist Professor Richard Moxon, describes the decades of research that contribute to the development of vaccines for life-threatening illnesses such as meningitis, and how immunisation has been our greatest public health intervention.
Mixed Oxford/Pfizer vaccine schedules generate robust immune response against COVID-19, finds Oxford-led study
30 June 2021
Alternating doses of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against COVID-19, according to researchers running the University of Oxford-led Com-COV study.